medicationPrescription only (US)Clopidogrel is an approved medicine; the cited literature reports trial outcomes, not dosing advice.
ClopidogrelBenefits, Dosage & Interactions
Also known as: Plavix
Clopidogrel is an antiplatelet medication that helps prevent blood clots. It is commonly marketed under the brand name Plavix. It is typically taken in the morning. The reported plasma half-life is about 0.5 hours, which shapes dosing frequency. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
How much Clopidogrel do people take?
Not stated here. The cited trials each used their own protocol amounts, and Clopidogrel is dosed by a prescriber or the approved product label — DoseRoutine records what you were told to take, it does not suggest an amount. Route reported: Oral (the route studied in the cited trials). Frequency reported: Set by the prescription or approved label, not by this record. These are amounts documented in the cited studies and labels for Clopidogrel — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 1822 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1822 human randomized trials and regulatory approval on file.
Plasma half-life
0.5–1 h
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Clopidogrel in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Clopidogrel entry is written from. Each number matches an inline marker above.
- [1]Ticagrelor versus clopidogrel in patients with acute coronary syndromesWallentin L, Becker RC, Budaj A, et al. · N Engl J Med · 2009 · Peer-reviewed · PMID 19717846
- [2]Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysisValgimigli M, Choi KH, Giacoppo D, et al. · Lancet · 2025 · Peer-reviewed · PMID 40902613
References & Evidence
Sources on this page that document Clopidogrel dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Clopidogrel?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Clopidogrel is an antiplatelet medication that helps prevent blood clots. It is commonly marketed under the brand name Plavix. It belongs to a class of drugs called thienopyridines, which work by inhibiting platelet aggregation. Platelets are small blood cells that play a crucial role in forming blood clots. By reducing the ability of platelets to clump together, clopidogrel helps keep blood flowing smoothly through the arteries.
Clopidogrel is primarily prescribed to individuals who have experienced, or are at high risk of experiencing, serious cardiovascular events such as heart attack, stroke, or peripheral artery disease. It is often used in combination with aspirin, particularly after certain procedures like stent placement, to maximize its clot-preventing effects. The half-life of clopidogrel is approximately 6 hours, meaning it takes about 6 hours for half of the drug to be eliminated from the body. It is typically taken once daily, usually in the morning, and can be taken with or without food. Clopidogrel is a prescription-only medication and its use requires careful medical supervision.
What does the research say about Clopidogrel?
Tap a section to expand.
Clopidogrel is a prodrug, meaning it is inactive until it is metabolized in the liver into its active form. This activation process primarily involves the cytochrome P450 (CYP) enzyme system, particularly CYP2C19. The active metabolite of clopidogrel selectively and irreversibly blocks the P2Y$_{12}$ subtype of ADP receptors on the surface of platelets. Adenosine diphosphate (ADP) is a chemical signal that promotes platelet activation and aggregation.
By binding to and blocking the P2Y$_{12}$ receptor, clopidogrel prevents ADP from binding and initiating the signaling cascade that leads to platelet activation. This inhibition reduces the mobilization of glycoprotein IIb/IIIa complexes to the platelet surface, which are essential for platelet cross-linking and the formation of a stable clot. Because this binding is irreversible, the platelets affected by clopidogrel remain inhibited for their entire lifespan, which is about 7-10 days. New platelets must be produced before full platelet function is restored. This sustained antiplatelet effect is key to clopidogrel's utility in preventing thrombotic events. (DrugBank)
Source for this section: Sources for How does Clopidogrel work?: Jumps to this entry in the sources and references list at the end of the page.
Clopidogrel's primary benefit is the reduction of serious cardiovascular events caused by blood clots. It is effective in preventing blood clots in a variety of clinical situations:
* **Acute Coronary Syndrome (ACS):** This includes conditions like unstable angina and myocardial infarction (heart attack). Clopidogrel, often in combination with aspirin, is a cornerstone of treatment to prevent recurrent events. (FDA label)
* **Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Artery Disease:** For individuals with a history of these conditions, clopidogrel helps reduce the risk of subsequent heart attacks or strokes. (FDA label)
* **Following Percutaneous Coronary Intervention (PCI) with Stent Implantation:** After a procedure to open narrowed or blocked coronary arteries using a stent, clopidogrel is crucial for preventing stent thrombosis (blood clots forming within the stent), which can lead to serious complications. (Cochrane, FDA label)
* **Atrial Fibrillation (off-label use):** In certain circumstances where warfarin or direct oral anticoagulants are contraindicated or not tolerated, clopidogrel (often with aspirin) may be considered, though it is generally less effective than these agents for stroke prevention in atrial fibrillation. This specific use is off-label and based on individual clinical assessment.
Numerous large-scale clinical trials have established the efficacy of clopidogrel in preventing thrombotic events. The CAPRIE trial demonstrated that clopidogrel was more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction, or vascular death in patients with a history of these events. (PubChem)
The CURE study showed that the addition of clopidogrel to aspirin in patients with acute coronary syndrome significantly reduced the risk of death from cardiovascular causes, nonfatal myocardial infarction, or stroke. (NIH ODS)
The COMMIT/CCS-2 trial provided further evidence supporting the early use of clopidogrel in combination with aspirin for patients with suspected acute myocardial infarction. (PubChem)
For patients undergoing percutaneous coronary intervention with stent placement, trials like the CREDO and PCI-CURE studies have demonstrated the benefit of dual antiplatelet therapy (aspirin plus clopidogrel) in reducing ischemic events, including stent thrombosis. (NIH ODS)
Cochrane reviews have consistently supported the use of clopidogrel in various cardiovascular settings, concluding that it reduces the risk of serious vascular events when used appropriately in indicated populations. (Cochrane)
As with any medication, clopidogrel can cause side effects. The most common and significant side effect is an increased risk of bleeding. This can range from minor bleeding, such as bruising or nosebleeds, to more serious and potentially life-threatening bleeding episodes, including gastrointestinal bleeding or intracranial hemorrhage.
Common side effects include:
* Bleeding (e.g., bruising, nosebleeds, gum bleeding)
* Indigestion or upset stomach
* Diarrhea
* Abdominal pain
Less common but more serious side effects can include:
* Severe bleeding (e.g., blood in urine or stool, vomiting blood)
* Rash or itching
* Thrombotic Thrombocytopenic Purpura (TTP): A rare but serious blood disorder characterized by blood clots in small blood vessels, low platelet count, and red blood cell destruction. Symptoms may include fever, weakness, extreme paleness, yellow skin or eyes, small red or purple spots on the skin, and neurological changes. This is a medical emergency.
* Allergic reactions (e.g., swelling of the face, tongue, or throat; difficulty breathing)
Patients should report any unusual or excessive bleeding to their clinician immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Clopidogrel?: Jumps to this entry in the sources and references list at the end of the page.
Several important warnings are associated with clopidogrel use:
* **Bleeding Risk:** Clopidogrel increases the risk of bleeding. This risk is higher with higher doses, in elderly patients, in those with a history of bleeding disorders, and when combined with other medications that affect bleeding (e.g., NSAIDs, anticoagulants). Patients should be advised to watch for signs of bleeding and notify their clinician if they experience any unusual or prolonged bleeding. (FDA label)
* **Genetic Variations (CYP2C19):** Some individuals have genetic variations in the CYP2C19 enzyme, which is responsible for activating clopidogrel. Individuals who are 'poor metabolizers' of CYP2C19 convert fewer prodrug molecules into the active metabolite, leading to reduced antiplatelet effects and an increased risk of cardiovascular events. Genetic testing for CYP2C19 polymorphisms may be considered in certain clinical situations to guide treatment decisions. (FDA label, MedlinePlus)
* **Surgery and Dental Procedures:** Due to the increased bleeding risk, clopidogrel may need to be temporarily discontinued before elective surgery, dental procedures, or other invasive medical procedures. The decision to stop clopidogrel and the timing of discontinuation must be made by a clinician, balancing the risk of bleeding against the risk of thrombotic events if the medication is stopped. (Mayo Clinic)
* **Thrombotic Thrombocytopenic Purpura (TTP):** TTP has been reported rarely, sometimes after short-term exposure (<2 weeks). It is a life-threatening condition that requires urgent treatment. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Clopidogrel?: Jumps to this entry in the sources and references list at the end of the page.
Clopidogrel is contraindicated (should not be used) in individuals with:
* **Active Pathological Bleeding:** This includes conditions such as peptic ulcers or intracranial hemorrhage. The antiplatelet effects of clopidogrel would worsen such bleeding. (FDA label)
* **Hypersensitivity to the Drug Substance or Any Excipients:** A confirmed allergic reaction to clopidogrel or its components would prevent its use. (EMA SmPC)
* **Severe Liver Impairment:** Patients with severe liver disease may have altered metabolism of clopidogrel, potentially affecting its efficacy and/or increasing the risk of adverse effects. (EMA SmPC)
Careful consideration and clinical judgment are required when prescribing clopidogrel to patients with an increased risk of bleeding, even if not an absolute contraindication. This includes individuals with a history of gastrointestinal bleeding, recent trauma or surgery, or those concurrently taking other medications that increase bleeding risk. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Clopidogrel not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Combining clopidogrel with certain other medications can increase the risk of bleeding or reduce clopidogrel's effectiveness. It is crucial to inform your clinician about all medications, supplements, and herbal products you are taking.
* **Other Anticoagulants/Antiplatelets:** Concomitant use with other oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, apixaban, edoxaban) or other antiplatelet agents (e.g., prasugrel, ticagrelor, dipyridamole) significantly increases the risk of bleeding. Dual antiplatelet therapy (aspirin + clopidogrel) is often prescribed, but always under strict medical supervision due to the increased bleeding risk. (FDA label)
* **Nonsteroidal Anti-inflammatory Drugs (NSAIDs):** NSAIDs (e.g., ibuprofen, naproxen) can cause gastrointestinal irritation and bleeding. Combining them with clopidogrel further increases the risk of gastrointestinal bleeding. (FDA label)
* **Certain Proton Pump Inhibitors (PPIs):** Some PPIs, particularly omeprazole and esomeprazole, can inhibit the CYP2C19 enzyme, which is needed to activate clopidogrel. This can reduce the effectiveness of clopidogrel. While the clinical significance of this interaction is debated, alternative PPIs (e.g., pantoprazole) or other acid-reducing medications may be considered if a PPI is necessary. (FDA label, MedlinePlus)
* **CYP2C19 Inhibitors:** Other medications that inhibit CYP2C19 can also reduce clopidogrel's antiplatelet effect. Examples include fluoxetine, fluvoxamine, modafinil, voriconazole, and others. (DrugBank)
* **CYP2C19 Inducers:** Medications that induce CYP2C19 activity could potentially increase clopidogrel activation, although the clinical implications are less clear and may vary. (DrugBank)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Clopidogrel?: Jumps to this entry in the sources and references list at the end of the page.
Clopidogrel is typically taken once daily. It is often recommended to take it in the morning, but consistency in timing is more important than the exact time of day. It can be taken with or without food. Taking it with food may help to reduce stomach upset in some individuals. Always adhere to the specific dosing instructions provided by your clinician and the pharmacist. (FDA label)
Source for this section: Sources for When should you take Clopidogrel?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Clopidogrel is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Clopidogrel?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Omega-3 (Fish Oil) | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Fish Oil (High EPA) | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Krill Oil | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Curcumin | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Vitamin E | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Serrapeptase | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Bromelain | Caution | Compound pairConfidence: theoretical | Additive antiplatelet/antithrombotic effect increases bleeding risk.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments. |
| Vitamin K1 | Caution | Compound pairConfidence: theoretical | Vitamin K reverses vitamin K antagonist activity and shifts INR.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Keep vitamin K intake consistent; do not start or stop supplementation without INR monitoring. |
| Vitamin K2 | Caution | Compound pairConfidence: theoretical | Vitamin K2 can shift INR on warfarin.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Discuss with prescribing clinician before adding K2. |
Frequently asked questions about Clopidogrel
Clopidogrel is a medication. It is also known as Plavix. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
Clopidogrel is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Clopidogrel, it is typically taken in the morning and its approximate half-life is 0.5 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Clopidogrel carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Clopidogrel is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Clopidogrel is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 0.5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Clopidogrel with no sign-up.
Combining a medication like Clopidogrel with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Clopidogrel: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 0.5 hours is why protocols often split Clopidogrel across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Clopidogrel clears quickly (plasma half-life around 0.5 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Clopidogrel the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Not stated here. The cited trials each used their own protocol amounts, and Clopidogrel is dosed by a prescriber or the approved product label — DoseRoutine records what you were told to take, it does not suggest an amount. Route reported: Oral (the route studied in the cited trials). Frequency reported: Set by the prescription or approved label, not by this record. These are amounts documented in the cited studies and labels for Clopidogrel — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Clopidogrel?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis(opens PubMed in a new tab)Lancet · 2025 · PMID 40902613 · https://pubmed.ncbi.nlm.nih.gov/40902613/
- 2.Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis(opens PubMed in a new tab)JAMA Cardiol · 2024 · PMID 38506796 · https://pubmed.ncbi.nlm.nih.gov/38506796/
- 3.Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis(opens PubMed in a new tab)JAMA Neurol · 2022 · PMID 34870698 · https://pubmed.ncbi.nlm.nih.gov/34870698/
- 4.Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis(opens PubMed in a new tab)JAMA Cardiol · 2026 · PMID 42201709 · https://pubmed.ncbi.nlm.nih.gov/42201709/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a601040.html
- PubChem CID 115366(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/115366
Verify at
Publisher search links for Clopidogrel. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Clopidogrel?
Plain-text summary, safe to quote verbatim:
Clopidogrel is an antiplatelet medication that helps prevent blood clots. It is commonly marketed under the brand name Plavix. It is typically taken in the morning. The reported plasma half-life is about 0.5 hours, which shapes dosing frequency. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Source: DoseRoutine — https://doseroutine.com/library/clopidogrel
Clopidogrel cheat sheet
DoseRoutine cheat sheet · Medication
Clopidogrel
Clopidogrel is an antiplatelet medication that helps prevent blood clots. It is commonly marketed under the brand name Plavix.
Evidence
Strong
1822 human randomized trials and regulatory approval on file.
Studied range
Not stated here. The cited trials each used their own protocol amounts, and Clopidogrel is dosed by a prescriber or the approved product label — DoseRoutine records what you were told to take, it does not suggest an amount.
Route
Oral (the route studied in the cited trials)
Frequency studied
Set by the prescription or approved label, not by this record
Half-life
0.5–1 h
Timing
in the morning
Storage
Room temperature, in the original container, away from moisture
Prescription only (US)Clopidogrel is an approved medicine; the cited literature reports trial outcomes, not dosing advice.
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/clopidogrel
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Clopidogrel — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/clopidogrel
What compounds are similar to Clopidogrel?
Others in the medication category or studied for the same goals.